iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market & Pipeline Drugs Market Analysis to 2020” is a 150 page report with 74 Figures and 10 Tables. This report analyses the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease - Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market. The Alzheimer’s Disease Drugs Market has been analyzed from 7 View Points: 1. Alzheimer’s Disease - Drugs Sales and Forecast 2. Alzheimer’s Disease - Pipeline Drugs Sales Forecast 3. Alzheimer’s Disease Drugs - Country Wise Market and Forecast 4. Alzheimer’s Disease - Country Wise Prevalence and Forecast 5. Alzheimer’s Disease - Pipeline Drugs Clinical Trials Analysis 6. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market 7. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows: 1. Exelon 2. Razadyne/Reminyl 3. Memary 4. Ebixa 5. Aricept 6. Rivastach 7. Namenda 8. Nootropil 9. Namzaric The 7 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows: 1. Solanezumab 2. ABT-126 3. idalopirdine 4. Gantenerumab 5. Crenezumab 6. Lu AE58054 7. BIIB037 The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows: 1. United States 2. France 3. Germany 4. Italy 5. Spain 6. United Kingdom 7. Japan 8. China 9. India The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows: 1. Strategic Alliance 2. Licensing Agreement 3. Collaboration Deals 4. Mergers and Acquisitions Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Alzheimers%20Disease%20Drugs%20Market%20Analysis Contact US iGATE Research PVT LTD Ravi Sinha Sales Manager Marketing and Sales Divison Email: ravi.sinha@igateresearch.com Contact: +91-858-684-0791, +91-706-527-9335 (INDIA) Web: www.igateresearch.com

1. © iGATE Research Page 1 of 17 www.igateresearch.com

2. © iGATE Research Page 2 of 17 www.igateresearch.com
Global Alzheimer’s Disease Drugs Market Overview
Alzheimer’s disease is a devastating condition for those afflicted as well as their family
members and caregivers; the situation is only getting worse as the population ages. With the
ageing global population, the number of patients suffering from Alzheimer’s disease is
predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high
reward market. Drugs currently available in the market have reached maturity; patent of
leading drugs have expired. The current unmet needs represent a huge opportunity for
pharmaceutical companies which are developing targeted novel therapies.
Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis: In 2014, the global
market for Alzheimer’s disease drugs was dominated by Namenda and Exelon. Aricept and
Memary stands at the third and fourth spot respectively in terms of Alzheimer’s disease drugs
sales in 2014. Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in
the Alzheimer’s disease market. With the patent expiration of popular drugs the sales of the
Alzheimer’s drugs has also declined. However, there are several pipeline drugs like
Solanezumab, Gantenerumab, Crenezumab and Lu AE58054 among others which are likely to
hit the market during the period 2017 - 2020.
Global Alzheimer’s Disease Country Wise Analysis: In the Alzheimer’s disease drugs market,
the United States is the largest market. Japan is the second leading market for Alzheimer’s
disease drugs market accounting for XXX% market share in 2014. China stands at the third spot
in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the
same year. The EU5 countries together accounted for over XXX% share of the global
Alzheimer’s disease drugs market in 2014.
iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market & Pipeline Drugs
Market Analysis to 2020” is a 150 page report with 74 Figures and 10 Tables. This report
analyses the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and
Clinical Trials Analysis, Alzheimer’s Disease - Country Wise Drugs Market, Country Wise
Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape,
Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s
Disease Drugs Market.

3. © iGATE Research Page 3 of 17 www.igateresearch.com
The Alzheimer’s Disease Drugs Market has been analyzed from 7 View Points:
1. Alzheimer’s Disease - Drugs Sales and Forecast
2. Alzheimer’s Disease - Pipeline Drugs Sales Forecast
3. Alzheimer’s Disease Drugs - Country Wise Market and Forecast
4. Alzheimer’s Disease - Country Wise Prevalence and Forecast
5. Alzheimer’s Disease - Pipeline Drugs Clinical Trials Analysis
6. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market
7. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research
The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:
1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric
The 7 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:
1. Solanezumab
2. ABT-126
3. idalopirdine
4. Gantenerumab
5. Crenezumab
6. Lu AE58054
7. BIIB037

4. © iGATE Research Page 4 of 17 www.igateresearch.com
The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:
1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India
The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:
1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions
Source of Information
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports. This report is built by using
data and information sourced from Proprietary Information Database, Primary and Secondary
Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified
professionals with deep industry experience and expertise.

5. © iGATE Research Page 5 of 17 www.igateresearch.com
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small
Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper,
Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on
the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report,
Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

6. © iGATE Research Page 6 of 17 www.igateresearch.com
About Us
iGATE RESEARCH is a global specialist in the field of Market Research, Analytics and
Consulting Services. We serve as a one stop shop for all the market and industry research needs
including Syndicated Research, Customized Research and Analytics Services. iGATE Research is
a gateway of information for various companies, whether it is Building a Strategy, or
Identifying Business Opportunity, Product Expansion, Market/Business Expansion, Competition
Assessment, etc. Combining deep understanding of the industry along with the expertise, we
help our clients in making better Business decisions.
At iGATE, we have a dedicated team of highly qualified and skilled professionals with deep
industry experience and expertise to manage complex report. We aim to offer high quality
Research Solutions to clients across multiple industries including Healthcare, Life Sciences,
Travel and Tourism, Retail, IT, Telecom, Consumer Retailing among others. We strive to
surpass our client’s expectations with every single project report.
iGATE Research team is comprised of Professionals having degree in Engineering, Management
Professionals, Biotech and other experts from relevant fields. The extensive background of our
team enables us to advise clients on a range of business initiatives, product testing, Market
entry, business opportunity, formulate strategy, etc which helps them in making informed
Business decisions.
For more information Visit: www.igateresearch.com
Email: info@igateresearch.com

7. © iGATE Research Page 7 of 17 www.igateresearch.com
Published
By
iiGGAATTEE RREESSEEAARRCCHH
Phone: +91-858-684-0791 (India)
+91-706-527-9335 (India)
Email: info@igateresearch.com
Internet: www.igateresearch.com
© Global Alzheimer’s Disease Drugs Market & Pipeline Drugs Market Analysis to 2020
iGATE Research Pvt. Ltd., 2015
Edition 1.0
All Rights Reserved.
No part of this Publication may be reproduced or transmitted
in any form or by any means, electronic or mechanical, including
photocopying, recording, or by any information storage
and retrieval system, without permission in
writing from the publisher.

8. © iGATE Research Page 8 of 17 www.igateresearch.com
Table of Contents
1. Executive Summary
2. Global Alzheimer’s Disease - Drugs Market and Prevalence Analysis
2.1 Global Alzheimer’s Disease - Drugs Market and Forecast (2010 - 2020)
2.2 Global Alzheimer’s Disease - Prevalence and Forecast (2010 - 2020)
3. Global Alzheimer’s Disease - Country Wise Market Share and Forecast (2013 - 2020)
4. Global Alzheimer’s Disease - Drugs Sales and Forecast To 2020
4.1 Exelon (Rivastigmine) Sales and Forecast
4.2 Razadyne/Reminyl Sales and Forecast
4.3 Memary (Memantine) Sales and Forecast
4.4 Ebixa (Memantine) Sales and Forecast
4.5 Aricept (Donepezil) Sales and Forecast
4.6 Rivastach Sales and Forecast
4.7 Namenda (Memantine) Sales and Forecast
4.8 Nootropil (Piracetam) Sales and Forecast
4.9 Namzaric (Memantine and Donepezil) Sales and Forecast
5. Global Alzheimer’s Disease - Pipeline Drugs Analysis and Sales Forecast
5.1 Solanezumab Drugs Analysis and Sales Forecast
5.1.1 About Solanezumab
5.1.2 Clinical Trials
5.1.3 Solanezumab Drugs Sales Forecast
5.2 ABT-126 Drugs Analysis and Sales Forecast
5.2.1 About ABT-126
5.2.2 Clinical Trials
5.2.3 ABT-126 Drugs Sales Forecast
5.3 Idalopirdine Drugs Analysis and Sales Forecast
5.3.1 About Idalopirdine
5.3.2 Clinical Trials
5.3.3 Idalopirdine Drugs Sales Forecast

9. © iGATE Research Page 9 of 17 www.igateresearch.com
5.4 Gantenerumab Drugs Analysis and Sales Forecast
5.4.1 About Gantenerumab
5.4.2 Clinical Trials
5.4.3 Gantenerumab Drugs Sales Forecast
5.5 Crenezumab Drugs Analysis and Sales Forecast
5.5.1 About Crenezumab
5.5.2 Clinical Trials
5.5.3 Crenezumab Drugs Sales Forecast
5.6 Lu AE58054 Drugs Analysis and Sales Forecast
5.6.1 About Lu AE58054
5.6.2 Clinical Trials
5.6.3 Lu AE58054 Drugs Sales Forecast
5.7 BIIB037 Drugs Analysis and Sales Forecast
5.7.1 About BIIB037
5.7.2 Clinical Trials
5.7.3 BIIB037 Drugs Sales Forecast
6. Alzheimer’s Disease Drugs Market and Prevalence - Country Wise Analysis
6.1 United States - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.1.1 United States - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.1.2 United States - Alzheimer’s Disease Prevalence and Forecast (2010 - 2020)
6.2 France - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.2.1 France - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.2.2 France - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)
6.3 Germany - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.3.1 Germany - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.3.2 Germany - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)
6.4 Italy - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.4.1 Italy - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.4.2 Italy - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)
6.5 Spain - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.5.1 Spain - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.5.2 Spain - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)
6.6 United Kingdom - Alzheimer’s Disease Drugs Market and Prevalence Analysis

10. © iGATE Research Page 10 of 17 www.igateresearch.com
6.6.1 United Kingdom - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.6.2 United Kingdom - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)
6.7 Japan - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.7.1 Japan - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.7.2 Japan - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)
6.8 China - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.8.1 China - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.8.2 China - Alzheimer’s Disease Prevalence and Forecast (2010 - 2020)
6.9 India - Alzheimer’s Disease Drugs Market and Prevalence Analysis
6.9.1 India - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020)
6.9.2 India - Alzheimer’s Disease Prevalence and Forecast (2010 - 2020)
7. Global Alzheimer’s Disease Drugs Market - Major Deals Analysis
7.1 Global Alzheimer’s Disease Drugs Market - Strategic Alliance
7.2 Global Alzheimer’s Disease Drugs Market - Licensing Agreement
7.3 Global Alzheimer’s Disease Drugs Market - Collaboration Deals
7.4 Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions
8. Global Alzheimer’s Disease Drugs Research - Funding Analysis
8.1 National Institute of Health (2011 - 2016)
8.2 Alzheimer's Association (2011 - 2014)
8.3 Cure Alzheimer’s Fund (2008 - 2014)
8.4 Alzheimer’s Drug Discovery Foundation (2008 - 2013)
8.5 BrightFocus Foundation (2010 - 2014)
9. Global Alzheimer’s Disease Drug Market - Driving Factors
9.1 Growing Aging Population
9.1.1 Global Ageing Indicators
9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050
9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 -
2050
9.2 Unmet Medical Needs
9.3 Strong Pipeline Candidate Expected to Drive Alzheimer’s Disease Drugs Market

11. © iGATE Research Page 11 of 17 www.igateresearch.com
9.4 Future Drugs for Disease Modification in Alzheimer’s Disease
10. Global Alzheimer’s Disease Drug Market - Challenges
10.1 Lack of Validated Targets & Lack of Animal Models
10.2 Barriers in the Design and Implementation of Clinical Trials
10.3 Barriers in Academia & Regulatory Issues
10.4 Alzheimer’s Drug Failure: Insinuation for Future R&D in Neuroscience
10.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies
10.6 Research Setbacks and Stepping Stones
10.7 Country Wise Barriers to Growth for Alzheimer’s Disease Drugs Market
10.7.1 Unite States
10.7.2 France
10.7.3 Germany
10.7.4 United Kingdom
10.7.5 Japan
10.7.6 China
10.7.7 India

12. © iGATE Research Page 12 of 17 www.igateresearch.com
List of Figures:
Figure 2-1: Global - Alzheimer’s Disease Drugs Market (Million US$), 2010 - 2014
Figure 2-2: Global - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 2-3: Global - Alzheimer’s Disease Prevalence (Million), 2010 - 2014
Figure 2-4: Global - Forecast for Alzheimer’s Disease Prevalence (Million), 2015 - 2020
Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2014
Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2015 - 2020
Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2014
Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2015 - 2020
Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2014
Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2015 - 2019
Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2014
Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2015 - 2020
Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2014
Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2015 - 2019
Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2014
Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2015 - 2020
Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2014
Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2015 - 2020
Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2014
Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2015 - 2020
Figure 4-17: Global - Forecast for Namzaric Drugs Sales (Million US$), 2015 - 2020
Figure 5-1: Global - Forecast for Solanezumab Drugs Sales (Million US$), 2017 - 2020
Figure 5-2: Global - Forecast for ABT-126 Drugs Sales (Million US$), 2017 - 2020
Figure 5-3: Global - Forecast for Idalopirdine Drugs Sales (Million US$), 2017 - 2020
Figure 5-4: Global - Forecast for Gantenerumab Drugs Sales (Million US$), 2017 - 2020
Figure 5-5: Global - Forecast for Crenezumab Drugs Sales (Million US$), 2018 - 2020
Figure 5-6: Global - Forecast for Lu AE58054 Drugs Sales (Million US$), 2017 - 2019
Figure 5-7: Global - Forecast for BIIB037 Drugs Sales (Million US$), 2019 - 2020
Figure 6-1: United States - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-2: United States - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-3: United States - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2014
Figure 6-4: United States - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-5: France - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-6: France - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020

13. © iGATE Research Page 13 of 17 www.igateresearch.com
Figure 6-7: France - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2014
Figure 6-8: France - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-9: Germany - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-10: Germany - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-11: Germany - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2014
Figure 6-12: Germany - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-13: Italy - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-14: Italy - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-15: Italy - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2014
Figure 6-16: Italy - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-17: Spain - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-18: Spain - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-19: Spain - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2014
Figure 6-20: Spain - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-21: United Kingdom - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-22: United Kingdom - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-23: United Kingdom - Alzheimer’s Disease Prevalence (Thousand), 2012 - 2014
Figure 6-24: United Kingdom - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-25: Japan - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-26: Japan - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-27: Japan - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2014
Figure 6-28: Japan - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-29: China - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-30: China - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-31: China - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2014
Figure 6-32: China - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 6-33: India - Alzheimer’s Disease Drugs Market (Million US$), 2013 - 2014
Figure 6-34: India - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2015 - 2020
Figure 6-35: India - Alzheimer’s Disease Prevalence (Thousand), 2010 - 2014
Figure 6-36: India - Forecast for Alzheimer’s Disease Prevalence (Thousand), 2015 - 2020
Figure 8-1: National Institute of Health - Alzheimer’s Disease Research Funding (Million US$), 2011 - 2014
Figure 8-2: National Institute of Health - Forecast for Alzheimer’s Disease Research Funding (Million US$),
2015 - 2016
Figure 8-3: Alzheimer’s Association - Alzheimer’s Disease Research Funding (Million US$), 2011 - 2014
Figure 8-4: Cure Alzheimer’s Fund - Alzheimer’s Disease Research Funding (Million US$), 2008 - 2014

14. © iGATE Research Page 14 of 17 www.igateresearch.com
Figure 8-5: Alzheimer’s Drug Discovery Foundation - Alzheimer’s Disease Research Funding (Million US$),
2008 - 2013
Figure 9-1: Worldwide - Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009,
2025 & 2050
Figure 9-2: Worldwide - Old-Age Dependency Ratio: Major Areas, 2009 & 2050
Figure 9-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 - 2050
Figure 9-4: Global - Forecast for Alzheimer’s Disease Pipeline Drugs Market (Million US$), 2017 - 2020
Figure 10-1: Unsuccessful Alzheimer’s Drug Development (Number), 1998 - 2011

15. © iGATE Research Page 15 of 17 www.igateresearch.com
List of Tables:
Table 3-1: Country Wise - Alzheimer’s Disease Drugs Market Share (Percent), 2013 - 2014
Table 3-2: Country Wise - Forecast for Alzheimer’s Disease Drugs Market Share (Percent), 2015 - 2020
Table 7-1: Global Alzheimer’s Disease Drugs Market - Strategic Alliance, 2003 - 2015
Table 7-2: Global Alzheimer’s Disease Drugs Market - Licensing Agreement, 2007 - 2015
Table 7-3: Global Alzheimer’s Disease Drugs Market - Collaboration Deals, 2005 - 2015
Table 7-4: Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions, 2008 - 2015
Table 8-1: BrightFocus Foundation - Alzheimer’s Disease Research Funding (Million US$), 2010 - 2014
Table 9-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
Table 9-2: Global - Population (Number), 2011/2012 - 2050
Table 9-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium
Variant)

16. © iGATE Research Page 16 of 17 www.igateresearch.com
Order the Report
Report Title: Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Market
Analysis to 2020
To Order the Report Visit:
http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Alzheimers%20Disease%
20Drugs%20Market%20Analysis
Single User License US$ 1,100
Hard-copy Mail Delivery US$ 1,250
CD-ROM Mail Delivery US$ 1,200
Multi User License US$ 1,600
For More Details Visit:
http://www.igateresearch.com/

17. © iGATE Research Page 17 of 17 www.igateresearch.com
Contact US
iGATE RESEARCH PVT. LTD.
Web: www.igateresearch.com
To order the Report:
E-Mail: info@igateresearch.com
Contact No. : +91-858-684-0791, +91-706-527-9335/9336 (INDIA)
For Report Related Query:
E-Mail: ravi.sinha@igateresearch.com
Contact No. : +91-858-684-0791, +91-706-527-9335 (INDIA)
Follow US
Facebook: https://www.facebook.com/pages/IGATE-Research/1569079456648005?sk=timeline
Twitter: https://twitter.com/IgateResearch
You Tube: https://www.youtube.com/channel/UCOr7KNn4JfTwk5_kQjj-xrQ
Google+: https://plus.google.com/110560526954506242845/posts
Linkedin:https://www.linkedin.com/profile/view?authType=NAME_SEARCH&locale=en_US&id=
374611590&trk=tyah&trkInfo=tarId%3A1414504898315%2Ctas%3Aigate+research%2Cidx%3A1-1-
1&authToken=YgR7